跳至主要内容
临床试验/NCT03083522
NCT03083522已完成3 期

Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet - A Randomized, Double-blinded, Placebo Controlled, Multi-center Pilot Study

Chan-Yong Jeon1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年3月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Changes from baseline in visual analogue scale

研究概览

简要总结

The Purpose of this trial is to investigate the efficacy and safety of Ojeok-san(OJS) on Korean Patients With Cold Hypersensitivity in the Hands

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 59 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female subjects aged 19 to 59 years have a complaint of CHH.
  • Patients must include at least one or more of the following symptoms:
  • Those who have the symptoms of CHH in normal temperature which most individuals feel no cold;
  • Those who have the symptoms of extremely cold hands in cold temperature exposure;
  • Those who are on the return to a warmer environment, the symptoms of cold hands is not completely rewarmed;
  • Those who have 4 cm or greater of VAS CHH score;
  • A thermal differences between the palm (PC8) and the upper arm (LU4) may be higher than 0.3℃;
  • Those who can comply with all study-related procedures, medications, and evaluations;
  • Given a written informed consent form.

排除标准

  • Patients with calcium antagonists or beta-blockers with the purpose of treating CHH;
  • Those who have one or more finger gangrene or ulceration;
  • Those who are diagnosed by hypothyroidism or currently medicated to thyroid drugs;
  • Those who are diagnosed by autoimmune disease or have a positive ANA test result;
  • Those who are diagnosed by carpal tunnel syndrome or have a positive Tinel and Phalen's tests;
  • Those who are diagnosed with cervical disc herniation or (malignant) tumor disease;
  • Those who are diagnosed with diabetes;
  • Those who are currently medicated to drugs that may affect to CHH symptoms, such as anticoagulants etc;
  • Those who have moderate level of liver dysfunction (each of AST, ALT greater than 100 IU/L) or kidney dysfunction (Cr 2.0mg/dL);
  • Those who do not (cannot) abide by treatment and follow up due to the mental illness such as behavior disorder, depression, anxiety neurosis, schizophrenia, or serious mental illness;
  • Those who are Diagnosed with moderate anemia and hematologic disorders (adult non-pregnant women hemoglobin (Hgb) level less than 7g/dL, hematocrit (Hct) level less than 26%, white blood cell (WBC) level greater than 11,000/mm3);
  • Those whose systolic blood pressure (SBP) 180mmHg or diastolic blood pressure (DBP) is greater than 100 mmHg based on average value of at least 2 measurements;
  • Those who are suspected arrhythmia that showing up on ECG, or diagnosed by heart diseases, such as, ischemic heart disease and so on;
  • Those who are addicted to alcohol or drugs;
  • Those who are pregnant (positive urine-HCG) or lactating or have the chances of pregnancy;
  • Those who are diagnosed with malignant tumor
  • Those who are currently participated in other clinical trials;
  • Those who are unable to understand and speak Korean;
  • Those who are judged to be inappropriate for the clinical study by the researchers.

研究组 & 干预措施

OJS group

Experimental

admission to Ojeok-san granule

干预措施: Ojeok-San (Drug)

Placebo Group

Placebo Comparator

admission to placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Changes from baseline in visual analogue scale

时间窗: At baseline, week 4, 8, 12

次要结局

  • Liver function tests(At screening visit, week 8)
  • Changes from baseline in body temperature(At baseline, week 4, 8, 12)
  • Changes from baseline in WHOQoL-BREF(At baseline, week 4, 8, 12)
  • Changes from baseline in cold stress test(At baseline, week 8)
  • Vital Sign(every visit)
  • Kidney function test(At screening visit, week 8)
  • complete blood count(At screening visit, week 8)
  • Adverse event(At week 4, 8, 12)

研究者

发起方
Chan-Yong Jeon
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Chan-Yong Jeon

PhD

Gachon University Gil Oriental Medical Hospital

研究点 (1)

Loading locations...

相似试验